Skip to content
Back to Guavy Wire
Stocks

Tech Outspends Pharma in Record Research Spend

Instruments
MRK
Share

Big Tech has surpassed Big Pharma in research and development (R&D) spending. According to R&D World, nine tech companies spent around $283 billion on R&D in 2025, more than twice the $124.7 billion spent by pharma's top 10 companies.

Alphabet leads in R&D spending at $61.1 billion, followed closely by Meta with $57.4 billion. Together, the two spent roughly $118.5 billion, which is 7.5 times Merck's $15.8 billion and 8.9 times Eli Lilly's $13.3 billion.

NVIDIA raised its R&D spending by 43% to $18.5 billion in its fiscal year ended January 25, 2026, exceeding both Merck and Lilly's spending in 2025. OpenAI spent around $19 billion on R&D while generating only $13 billion in revenue.

Meanwhile, drugmakers are increasingly paying for access to what Big Tech builds, with the total value of pharma AI partnerships jumping 120% from 2024 to 2025, according to GlobalData figures.

More on Stocks

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

© 2026 Guavy Inc